What happened with LIVN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
LivaNova’s largest business supplies equipment and disposable products that keep blood circulating and exchange oxygen and carbon dioxide during heart surgery. Hospitals, healthcare institutions and distributors pay for its heart-lung machines, including the Essenz Perfusion System, and consumables such as oxygenators and tubing. It also provides installation, repair and maintenance, though services contribute relatively little revenue.
The other substantial business sells the VNS Therapy System for drug-resistant epilepsy and difficult-to-treat depression. An implanted generator sends electrical pulses through a lead to the vagus nerve; the generator can be replaced when its battery runs out without removing the lead. LivaNova is also developing and clinically testing aura6000 for obstructive sleep apnea, rather than selling it as an established therapy.
Sales depend substantially on insurers and other healthcare payers covering treatment and providing adequate reimbursement. LivaNova must obtain and maintain regulatory approvals and cannot promote devices for uses outside their approved labeling. Production also relies on some primary or single-source component suppliers, which strict medical-device standards can make difficult to replace quickly.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
LivaNova’s results hinge on epilepsy implant adoption and demand for cardiac-surgery equipment and consumables; important cardiopulmonary rivals Terumo, Maquet and Spectrum Medical are absent from this list.
NeuroPace competes for drug-resistant epilepsy patients with implants that detect seizure patterns in the brain and respond with stimulation, while LivaNova sells implants that stimulate the vagus nerve. Watch NeuroPace’s initial RNS implant sales among U.S. adults with drug-resistant focal epilepsy for evidence of adoption of this competing treatment.
Medtronic competes with LivaNova for drug-resistant epilepsy patients through devices that stimulate deep within the brain, versus LivaNova’s vagus-nerve implants. It also sells systems that recover patients’ blood during surgery for reinfusion, competing with LivaNova’s autotransfusion products; developments in these two product groups matter more to this comparison than Medtronic’s diabetes business.
Haemonetics’ Cell Saver competes directly with LivaNova’s systems for collecting, processing and reinfusing blood lost during surgery. Its hospital cell-salvage business is the relevant area to watch for competition on reliability, ease of use, service and price—not its plasma-collection sales.
Inspire Medical Systems already sells implants that stimulate the nerve controlling the tongue to keep the airway open during sleep, competing with LivaNova’s aura6000 therapy and planned U.S. entry. Watch its sales to U.S. hospitals and surgery centers for patients with moderate-to-severe obstructive sleep apnea who cannot tolerate or have failed positive-airway-pressure treatment.
Nyxoah’s Genio implant stimulates the nerves controlling the tongue to treat obstructive sleep apnea, competing with LivaNova’s aura6000 program; it uses external power rather than an implanted battery. Genio began generating U.S. sales in September 2025, making its U.S. sales progress worth watching ahead of LivaNova’s expected 2027 entry.
Inspire Medical Systems, Inc. earningsINSP
Inspire Medical Systems’ report will show U.S. hospital and surgery-center demand for its sleep-apnea implant, a read-through on the market LivaNova plans to enter with aura6000.
Watch Inspire’s U.S. sales to hospitals and surgery centers. Stronger sales would show that patients who cannot tolerate or have not benefited from positive-airway-pressure treatment are adopting an implant, giving LivaNova an established pool of demand to compete for; weaker sales would suggest adoption remains a hurdle, not that aura6000 will perform the same way.
Neuropace, Inc. earningsNPCE
NeuroPace’s report will show U.S. uptake of its brain-responsive epilepsy implant, an alternative competing with LivaNova’s vagus-nerve stimulation treatment.
Watch initial RNS implant sales among U.S. adults with drug-resistant focal epilepsy. Rising sales would show adoption of brain-responsive stimulation, strengthening an alternative to LivaNova’s vagus-nerve implants; weak sales would mean this competing approach has yet to show broad uptake, not that LivaNova’s own demand is proven.
LivaNova PLC earningsThis company
LivaNova’s report will show whether hospitals’ purchases of cardiopulmonary equipment and nerve-stimulation therapies can keep both businesses growing without squeezing margins.
Read Cardiopulmonary and Neuromodulation revenue alongside gross margin. Growth in both segments with a steady margin would show broad hospital demand is translating into profit; growth concentrated in one segment, or a falling margin, would point to a narrower demand base or product mix and costs eating into the gains.
Haemonetics Corporation earningsHAE
Haemonetics’ report will show hospital demand for its cell-salvage business, which competes directly with LivaNova’s autotransfusion systems.
Focus on Haemonetics’ hospital cell-salvage business, not plasma-collection sales. Stronger sales would show hospitals buying more of a system that competes with LivaNova’s autotransfusion products, adding competitive pressure; weaker sales would mean less evidence of demand from this rival, not proof that LivaNova is gaining it.
Nyxoah SA earningsNYXH
Nyxoah’s report will show U.S. sales progress for its Genio implant, an early signal of the competing market LivaNova plans to enter with aura6000.
Watch Genio’s U.S. sales, which began in September 2025. Growth would show early U.S. adoption of a tongue-nerve implant for sleep apnea, giving LivaNova an established market to contest; slow sales would suggest uptake is still limited and demand for aura6000 remains unproven.
